The effects of Canabidiol in the treatment of asthma induced by House Dust Mite in an experimental model, and its effects on purinergic receptors P2X7, P2Y6 and P2Y2 and on the signaling of SOCS - JAK - STAT proteins

• Grant number: 19/03275-7
• Support Opportunities: Regular Research Grants
• Start date: July 01, 2019
• End date: June 30, 2021
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Manoel Carneiro de Oliveira Junior
• Grantee: Manoel Carneiro de Oliveira Junior
• Host Institution: Universidade Nove de Julho (UNINOVE). Campus Vergueiro. São Paulo , SP, Brazil

Abstract

Asthma is a chronic inflammatory disease of the airways, which has as a consequence a worsening of daily activities and quality of life of the disease carrier, characterized by a process of remodeling and hyperresponsiveness of the airways, causing a airflow limitation of the asthmatic individual. With regard to treatment much is known about the improvement of the clinical picture with alternative therapies such as physical activity, however, little is known regarding alternative therapies of a drug such as for example the use of the substrate of canabis known as cannabidiol (CBD), much has been researched the effects of this treatment with neurodegenerative diseases, but its effects in relation to the respiratory tract are still unknown mainly in effects on both animal model and clinical models. Thus, the present study aims to evaluate the effects of therapy with cannabidiol (CBD) on the purinergic receptors P2X7, P2Y2 and P2Y6 and in the signaling of SOCs, JAK and STAT proteins in the lungs and lymphatic organs (lymph nodes and spleen) as one of possible mediators of anti-inflammatory and bronchodilators effects, using an experimental model of asthma with HDM (House Dust Mite), and this model is more similar to the effects in humans. This project will be evaluated by sensitization of animals with HDM and only then administered cannabidiol (CBD). After the designated period will be evaluated the inflammation in the bronchoalveolar lavage, systemic and lung tissue, the levels of pro-inflammatory mediators such as cytokines TH2 (IL-5, IL-13 and TNF-alpha) In addition to the anti-inflammatory mediators (IL-10 and IL-1ra), Airway remodeling, pulmonary mechanics and bronchial hyperresponsiveness, in addition to the levels of exiled NO. It will also be evaluated the quantification of the gene expression of the purinergic receptors by PCR analysis. (AU)